Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Annual Meeting Results
Summary
Crinetics Pharmaceuticals, Inc. held its annual meeting of stockholders on June 18, 2026. The meeting saw the election of three new Class II directors to the Board of Directors, with approximately 97% of the total outstanding shares eligible to be voted. Additionally, the stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The compensation of the Company's named executive officers was also approved on an advisory basis.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement